Mobile app version of munafa.biz
Login or Join
 Learn then Earn
stockMarketNEWS

 story : Spero's stock jumps 188% after GSK licenses experimental antibiotic #FinanceUSA #StockMarketNEWS Shares of Spero Therapeutics Inc. soared 188.4% in trading on Thursday morning after the company signed

@stockMarketNEWS 13 Days ago

Posted in: #FinanceUSA #StockMarketNEWS

Spero's stock jumps 188% after GSK licenses experimental antibiotic #FinanceUSA #StockMarketNEWS
Shares of Spero Therapeutics Inc. soared 188.4% in trading on Thursday morning after the company signed an exclusive license agreement with GlaxoSmithKline for its experimental antibiotic for complicated urinary tract infections. Spero's therapy, tebipenem HBr, is expected to enter Phase 3 clinical trials next year. If approved, it would offer patients an oral medication option instead of in-hospital intravenous therapy, the companies said. Spero is receiving million upfront, with at least 5 million in milestone payments. Spero's stock is down 85.4% this year, while the S&P 500 has declined 20.5%.


Munafa USA Munafa India Munafa NSE


Report

Login to follow story

More posts by @stockMarketNEWS

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme